Ixekizumab
Therapeutic Ixekizumab antibody from the original Taltz® commercial drug.
Reference Standard as Aliquots
Product Batch
| Expiry Date
| Brand & Origin
| Amount per Aliquot
| Select Quantity | Discount | Price per Aliquot
| |
|---|---|---|---|---|---|---|---|
2023.08 |
Taltz® DE |
4 mg |
aliquot |
Order on demand:
|
550,00 €
/aliquot
|
Biosimilars as Aliquots
Access Batch Specific Analytical Information
Evidentic’s Analytical Data Service includes a comprehensive array of methods to support the drug development process, including structure, aggregation, degree of isomerization, and N-glycans identification of the active pharmaceutical ingredient (API).
Product Information
Here you will find the product information for the reference product.
Taltz® / Ixekizumab Reference Product
| Drug name | Taltz® |
| INN | Ixekizumab |
| API type | Ixekizumab is a monoclonal antibody, produced in CHO cells by recombinant DNA technology. |
| Pharmacotherapeutic group | Immunosuppressants, interleukin inhibitors |
| ATC code | L04AC13 |
| Target of antibody | 17A (both IL-17A and IL-17A/F) |
| General function | Ixekizumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. |
| Short description | |
| Pharmacodynamic properties (Mechanism of action; Source EMA document) | Ixekizumab is an IgG4 monoclonal antibody that binds with high affinity (< 3 pM) and specificity to interleukin 17A (both IL-17A and IL-17A/F). Elevated concentrations of IL-17A have been implicated in the pathogenesis of psoriasis by promoting keratinocyte proliferation and activation, as well as in the pathogenesis of psoriatic arthritis and axial spondyloarthritis by driving inflammation leading to erosive bone damage and pathological new bone formation. Neutralisation of IL-17A by Ixekizumab inhibits these actions. Ixekizumab does not bind to ligands IL-17B, IL-17C, IL-17D, IL-17E or IL-17F. |
| Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | Ixekizumab modulates biological responses that are induced or regulated by IL-17A. Based on psoriatic skin biopsy data from a phase I study, there was a dose-related trend toward decreased epidermal thickness, a number of proliferating keratinocytes, T cells, and dendritic cells, as well as reductions in local inflammatory markers from baseline to day 43. As a direct consequence of treatment with Ixekizumab reduces erythema, induration and desquamation present in plaque psoriasis lesions. |
| Original license holder | Eli Lilly and Company (Ireland) Limited Dunderrow Kinsale Co. Cork Ireland |
| Marketing authorisation numbers | EU/1/15/1085/001 EU/1/15/1085/002 EU/1/15/1085/003 |
| Marketing authorisation holder | Eli Lilly and Company (Ireland) Limited Dunderrow Kinsale Co. Cork Ireland |
| Name of the manufacturer of the biological active substance | Eli Lilly Kinsale (Ireland) Limited Dunderrow Kinsale Co. Cork Ireland |
| Name and address of the manufacturer(s) responsible for batch release | Eli Lilly Italia S.p.A. Via Gramsci 731/733 50019 Sesto Fiorentino (FI) Italy |
| Max shelf life | 2 years |
| Storage conditions | 2°C – 8°C |
| List of excipients | Sucrose Polysorbate 80 Water for injections Sodium hydroxide may be used to adjust pH |
Support
Do you have a question about the product? Reach out to our team using the form below – we’d be happy to help you!
Ready to simplify your sourcing?
Here’s how to get started:
Select Your Licensed Molecules
Browse our shop and choose the licensed molecule(s) you need. Don’t worry if you can’t find the molecule you’re looking for – we can source it for you!
Get a Quote
Receive a confidential, non-binding quote for the molecule(s) you choose.
Get Qualified & We Deliver
Complete our quick qualification process, place your order, and we’ll ship your molecule(s) within days.
Do you have a question you'd like to ask us?
Here’s how to get started:
